Találati lista | Tudóstér

001-es BibID:	BIBFORM120802
035-os BibID:	(Scopus)85191357998 (WoS)001205799400001
Első szerző:	Ameri, Pietro
Cím:	A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function / Pietro Ameri, Valentina Mercurio, Piero Pollesello, Markus S. Anker, Johannes Backs, Antoni Bayes-Genis, Barry A. Borlaug, Daniel Burkhoff, Sergio Caravita, Stephen Y. Chan, Frances de Man, George Giannakoulas, Aránzazu González, Marco Guazzi, Paul M. Hassoun, Anna R. Hemnes, Cristoph Maack, Brendan Madden, Vojtech Melenovsky, Oliver J. Müller, Zoltan Papp, Soni Savai Pullamsetti, Peter P. Rainer, Margaret M. Redfield, Stuart Rich, Gabriele G. Schiattarella, Hall Skaara, Kostantinos Stellos, Ryan J. Tedford, Thomas Thum, Jean Luc Vachiery, Peter van der Meer, Sophie Van Linthout, Piotr Pruszczyk, Petar Seferovic, Andrew J. S. Coats, Marco Metra, Giuseppe Rosano, Stephan Rosenkranz, Carlo Gabriele Tocchetti
Dátum:	2024
ISSN:	1388-9842 1879-0844
Megjegyzések:	Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Drug Heart failure Pulmonary hypertension Therapy Translational
Megjelenés:	European Journal Of Heart Failure. - 26 : 4 (2024), p. 707-729. -
További szerzők:	Mercurio, Valentina Pollesello, Piero Anker, Markus S. Backs, Johannes Bayes-Genis, Antoni Borlaug, Barry A. Burkhoff, Daniel Caravita, Sergio Chan, Stephen Man, Frances de Giannakoulas, George González, Aránzazu Guazzi, Marco Hassoun, Paul M. Hemnes, Anna R. Maack, Christoph Madden, Brendan Melenovsky, Vojtech Müller, Oliver J. Papp Zoltán (1965-) (kardiológus, élettanász) Pullamsetti, Soni Savai Rainer, Peter P. Redfield, Margaret M. Rich, Stuart Schiattarella, Gabriele G. Skaara, Hall Stellos, Kostantinos Tedford, Ryan J. Thum, Thomas Vachiery, Jean Luc Meer, Peter van der Linthout, Sophie Van Pruszczyk, Piotr Seferović, Petar M. Coats, Andrew Metra, Marco Rosano, Giuseppe M. C. Rosenkranz, Stephan Tocchetti, Carlo Gabriele
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: